Quanterix Stock Price, News & Analysis
Company Description
Quanterix Corporation (NASDAQ: QTRX) is a life sciences company focused on ultra-sensitive biomarker detection that supports disease research, diagnostics, and drug development. The company develops and commercializes its proprietary Simoa® (Single Molecule Array) technology, which enables researchers to detect and quantify protein biomarkers in blood and other fluids at concentrations far below the limits of traditional, analog immunoassay technologies. According to company disclosures, Quanterix has been a trusted partner to the scientific community for nearly two decades and its technology has been cited in thousands of peer‑reviewed publications.
Core technology and platforms
Quanterix’s business centers on its Simoa bead-based and planar array platforms, which are designed to allow customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids. The company’s product portfolio, as described in public materials, includes:
- Simoa instruments, such as the HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
- Assay kits and related reagents for measuring specific biomarkers.
- Laboratory Developed Tests (LDTs) and assay services, including offerings like Simoa p‑Tau 217, Simoa NfL LDT, and Simoa p‑Tau 181 LDT.
- The Simoa Accelerator Laboratory, which provides contract biomarker testing services and custom assay development.
These platforms are used to support research and clinical applications in areas such as neurology, immunology/oncology, infectious diseases, and other fields where precise protein biomarker measurement is important.
Focus on neurology and neurodegeneration
Quanterix plays a prominent role in neurodegenerative disease research, particularly Alzheimer’s disease and multiple sclerosis (MS). Company announcements describe a portfolio of blood-based assays targeting phosphorylated tau (p‑Tau) and neurofilament light chain (NfL), biomarkers that are widely studied in Alzheimer’s and other neurological conditions.
For Alzheimer’s research, Quanterix has developed assays such as Simoa p‑Tau 217 and has launched commercial assays for p‑Tau 205 and p‑Tau 212. These tests are designed to enable precise detection of tau phosphorylation sites that are associated with early and progressive stages of Alzheimer’s disease. A Nature study highlighted by the company used a Quanterix p‑Tau 217 research assay on the fully automated HD‑X analyzer to assess Alzheimer’s Disease Neuropathological Changes in a large population-based cohort, illustrating how the platform can support large-scale epidemiological work.
In multiple sclerosis, Quanterix reports that multiplexed Simoa assays for GFAP (Glial Fibrillary Acidic Protein) and NfL establish a dual‑biomarker approach for monitoring disease activity and progression. Published research described by the company shows that serum NfL is used to predict relapses and acute disease activity, while GFAP is associated with progression independent of relapse activity. Quanterix also notes the existence of extensive Simoa‑based normative reference databases for these biomarkers, which help interpret individual patient results when combined with factors such as age, sex, and body mass index.
Acquisition of Akoya Biosciences and spatial biology
In 2025, Quanterix completed the acquisition of Akoya Biosciences, Inc., described as The Spatial Biology Company®. According to SEC filings and company press releases, the acquisition was carried out under an Amended and Restated Agreement and Plan of Merger involving a Quanterix subsidiary and Akoya. Through this transaction, Quanterix added multiplexed tissue imaging with single‑cell resolution to its portfolio and gained an installed base of 1,396 instruments associated with Akoya’s spatial biology platform.
Company disclosures state that the combined organization offers an integrated platform that connects biology across blood and tissue, linking Simoa‑based fluid biomarker detection with high‑plex spatial proteomics in formalin‑fixed, paraffin‑embedded (FFPE) tissue. Examples referenced in public materials include the Human FFPE Neurobiology Panel, which supports spatial analysis of protein expression in brain tissue, and applications in immuno‑oncology and metabolism using Akoya’s PhenoCycler‑Fusion system and related panels.
Quanterix Accelerator Laboratory and clinical testing
The Quanterix Accelerator Laboratory is described as a facility that leverages Simoa technology to support biopharmaceutical research, clinical testing, and custom assay development. Public statements note that the lab is certified under the Clinical Laboratory Improvement Amendments (CLIA) program and has been granted a New York State Department of Health clinical laboratory permit in the Clinical Chemistry category. The lab has developed more than 100 custom assays and has supported hundreds of global clinical trials across neurology, immunology/oncology, and infectious diseases.
Within the Accelerator Laboratory, Quanterix offers a Simoa NfL Laboratory Developed Test (LDT) and has indicated that additional clinical tests are planned. The lab also operates the Lucent Diagnostics brand, which provides advanced serum and plasma biomarker testing to clinical and research customers. This structure allows Quanterix to combine its assay development expertise with clinical testing capabilities for partners in pharma, biotech, and academia.
Geographic reach and markets served
Based on company and third‑party descriptions, Quanterix operates in North America, EMEA, and Asia Pacific. The company has highlighted partnerships with organizations in Asia‑Pacific, including entities in Singapore, Taiwan, and Australia, to expand access to its technologies and Alzheimer’s diagnostics offerings. Its products and services are used by clinical, pharmaceutical, and research partners who require highly sensitive biomarker detection in both exploratory and translational settings.
Financial reporting and corporate governance
Quanterix files periodic financial statements and current reports with the U.S. Securities and Exchange Commission (SEC). Recent Form 8‑K filings describe quarterly financial results, including breakdowns of product revenue, service and other revenue, collaboration and license revenue, and grant revenue. The filings also discuss non‑GAAP metrics such as adjusted EBITDA, adjusted gross margin, adjusted operating expenses, and adjusted cash usage, along with reconciliations and explanations of how management uses these measures.
Other SEC filings detail matters such as the completion of the Akoya acquisition, unaudited pro forma condensed combined financial statements, and shareholder votes on corporate governance topics. For example, stockholders have approved amendments to declassify the Board of Directors and to eliminate certain supermajority voting requirements. The company has also entered into a cooperation agreement with Kent Lake Partners LP that includes commitments to appoint a new independent director and adopt a majority voting standard in uncontested director elections.
Stock information and industry classification
Quanterix Corporation is listed on NASDAQ under the ticker QTRX. In industry classification systems, it is associated with testing laboratories within the broader Professional, Scientific, and Technical Services sector. Its focus on ultra‑sensitive biomarker detection, laboratory services, and spatial biology positions it within the life sciences tools and diagnostics ecosystem, supporting both research and clinical applications.
Use cases and applications
According to company communications, Quanterix technology is used to:
- Support Alzheimer’s disease research and diagnostics through blood‑based p‑Tau assays and related biomarkers.
- Enable multiple sclerosis monitoring with combined GFAP and NfL assays and associated normative data tools.
- Advance biomarker‑driven clinical trials in neurology, oncology, immunology, and infectious diseases via the Accelerator Laboratory.
- Integrate spatial proteomics and fluid biomarkers to connect tissue‑level and blood‑based biology in translational research.
These use cases are drawn from published studies and company press releases that describe how Simoa assays, spatial biology platforms, and reference databases are applied in real‑world research and clinical contexts.